Camzyos ® (mavacamten) — PDUFA
Sep 30
The FDA has granted the application Priority Review and assigned a PDUFA date of September 30, 2026.Source filing
BMY biotech catalysts & pipeline
BRISTOL MYERS SQUIBB CO · Data as of 2026-09-08
Upcoming catalysts
luspatercept — PDUFA
Mar 11
The FDA granted a Prescription Drug User Fee Act (PDUFA) date of March 11, 2027.Source filing
mezigdomide — PDUFA
May 13
The FDA accepted a New Drug Application for mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) in patients with relapsed or refractory multiple myeloma (RRMM), granting a PDUFA date of May 13, 2027.Source filing